Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort

Sánchez-Antolín, Gloria; Testillano, M.; Pascasio, J.M.; Rodríguez, Isidoro Narváez; Prieto, M.; Otero, Alejandra; Herrero, J.I.; Londoño, María-Carlota; Vázquez, Inmaculada Fernández; Castells, Lluı́s; Xiol, Xavier; Dieguez, Maria Luisa Gonzalez; Cristóbal, Mario Romero; Pons, José Antonio; Bartolomé, Sonia Pascual; Montero, J.L.; Arencibía, Ana; Lorente, Sara; Molina, Esther; Espinosa, María Dolores; Cuervas-Mons, Valentín; García, E. Fábrega

doi:10.1016/j.transproceed.2016.08.034

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was a multicenter retrospective study, including 28 HCV genotype 4 patients from 11 liver transplant centers. The SVR was 95.23% including patients with advanced fibrosis and cirrhosis [118].…”

Section: Sofosbuvir/simeprevir (Sim)mentioning

confidence: 97%

Liver Transplantation and HCV Genotype 4

Alghamdi¹,

Al–Hamoudi²

2021

Advances in Hepatology

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is a major indication for liver transplantation (LT) worldwide. Previous studies have shown a negative impact of HCV on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East HCV-G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre- and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1-infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

Section: Sofosbuvir/simeprevir (Sim)mentioning

confidence: 97%